<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623567</url>
  </required_header>
  <id_info>
    <org_study_id>CD2020-4-4155</org_study_id>
    <nct_id>NCT04623567</nct_id>
  </id_info>
  <brief_title>Efficacy Assessment of Chinese Herbal Medicine Jiangtang Tiaozhi Recipe Treating Participants With Glucose and Lipid Metabolism Disturbances</brief_title>
  <official_title>Efficacy Assessment of Chinese Herbal Medicine Jiangtang Tiaozhi Recipe Treating Participants With Glucose and Lipid Metabolism Disturbances and Associations Study Between Glucose and Lipid Metabolism Disturbances and Cardiovascular Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, positive drug parallel-controlled clinical trial in participants&#xD;
      with glucose and lipid metabolism disturbances. A total of 96 participants will be recruited&#xD;
      for the study, all of whom are diagnosed as type 2 diabetes mellitus combined with&#xD;
      dyslipidemia. The subjects will be divided randomly into two groups and treated with either&#xD;
      Jiangtang Tiaozhi Recipe or metformin. After 12 weeks of treatment, therapeutic effect of&#xD;
      Jiangtang Tiaozhi Recipe will be evaluated based on the changes of HbA1c, fasting blood&#xD;
      glucose, postprandial blood glucose, blood lipid, waist circumference, body mass index.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The diagnosis criteria of type 2 diabetes mellitus are in accordance to 1999 World Health&#xD;
      Organization (WHO) diabetes diagnostic criteria. The diagnosis criteria of dyslipidemia are&#xD;
      based on the Guidelines for the Prevention and Treatment of Dyslipidemia in Chinese adults&#xD;
      (2016, revision edition). The outcomes mainly include HbA1c, fasting blood glucose,&#xD;
      postprandial blood glucose, body weight, waist circumference, blood lipid and TCM symptom&#xD;
      score.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline HbA1c at 12 weeks</measure>
    <time_frame>0 week, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline Fasting Blood Glucose at 4 weeks, 8 weeks,12 weeks</measure>
    <time_frame>0 week, 4 weeks, 8 weeks,12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Postprandial Blood Glucose at 12 weeks</measure>
    <time_frame>0 week, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Low Density Lipoprotein at 12 weeks</measure>
    <time_frame>0 week, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Triglyceride at 12 weeks</measure>
    <time_frame>0 week, 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline Body Mass Index at 4 weeks, 8 weeks,12 weeks</measure>
    <time_frame>0 week, 4 weeks, 8 weeks,12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline Waist Circumference at 4 weeks, 8 weeks,12 weeks</measure>
    <time_frame>0 week, 4 weeks, 8 weeks,12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Total Cholesterol at 12 weeks</measure>
    <time_frame>0 week, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline High Density Lipoprotein at 12 weeks</measure>
    <time_frame>0 week, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline TCM Symptom Score at 12 weeks</measure>
    <time_frame>0 week, 12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Compositional and Functional Changes from Baseline Gut Microbiota at 12 weeks</measure>
    <time_frame>0 week, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Compositional and Functional Changes from Baseline Metabolites in blood and feces at 12 weeks</measure>
    <time_frame>0 week, 12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Jiangtang Tiaozhi Recipe Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jiangtang Tiaozhi formula granule (30g per bag), 1 bag per time, twice a day, take it with warm water after meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500mg metformin tablet per time, 3 times a day, take it with meals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jiangtang Tiaozhi recipe</intervention_name>
    <description>The Jiangtang Tiaozhi recipe is a combination of several Chinese herbs, which has been granted a patent (No. ZL 2013 1 0373659.7)</description>
    <arm_group_label>Jiangtang Tiaozhi Recipe Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>The metformin tablets (500mg) will be administrated.</description>
    <arm_group_label>Metformin Group</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 to 70 years at the time of their consent;&#xD;
&#xD;
          2. Diagnosed with type 2 diabetes;&#xD;
&#xD;
          3. TG≥1.7 mmol/L or LDL-C≥3.4 mmol/L;&#xD;
&#xD;
          4. BMI≥24.0 kg/m2 or male waist circumference≥90 cm, female waist circumference≥80 cm;&#xD;
&#xD;
          5. Failed to reach the normal standards of blood glucose and lipids after diet control&#xD;
             and exercise therapy before enrollment;&#xD;
&#xD;
          6. TCM Syndrome differentiation as excess heat in the stomach and intestines syndrome;&#xD;
&#xD;
          7. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1 diabetes, gestational diabetes, other special types of diabetes.&#xD;
&#xD;
          2. Diabetic complications were the main symptoms, that is, patients with serious heart,&#xD;
             lung, liver, kidney, brain complications or other serious primary diseases.&#xD;
&#xD;
          3. Patients with diabetic ketoacidosis, hyperosmolar nonketotic diabetic coma, severe&#xD;
             infection, and surgery in recent one month.&#xD;
&#xD;
          4. Have a history of serious gastrointestinal diseases, or are suffering from serious&#xD;
             gastrointestinal diseases, such as peptic ulcer, gastrointestinal bleeding,&#xD;
             gastroparesis, pyloric stenosis, gastric shunt, etc..&#xD;
&#xD;
          5. Psychiatric patients, alcoholism and/or psychoactive substances, drug abusers and&#xD;
             addicts.&#xD;
&#xD;
          6. Pregnant, preparing for pregnancy or lactation.&#xD;
&#xD;
          7. Patients who participated in other clinical studies within one month prior to&#xD;
             participating in this study or were participating in other clinical studies.&#xD;
&#xD;
          8. According to the judgment of the researcher, other diseases or conditions that reduce&#xD;
             the possibility of enrollment or complicate the enrollment, such as frequent changes&#xD;
             in working environment and unstable living environment, are likely to cause loss of&#xD;
             follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiaxing Tian, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiaxing Tian, PhD</last_name>
    <phone>+8601088001166</phone>
    <email>tina_yai@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guang'anmen Hospital, China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weidong Li</last_name>
      <phone>+8601088001552</phone>
      <email>gamhec@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jiaxing Tian</investigator_full_name>
    <investigator_title>Attending Physician, Department of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>dyslipidemias</keyword>
  <keyword>Jiangtang Tiaozhi Recipe</keyword>
  <keyword>randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

